TRVN Trevena Inc.

1.58
-0.12  -7%
Previous Close 1.7
Open 1.7
Price To Book 3.51
Market Cap 145918748
Shares 92,353,638
Volume 1,580,006
Short Ratio
Av. Daily Volume 4,388,491

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2, 2018. Noted January 28, 2019 that additional QT interval data required - trial to commence 1H 2019.
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 2b endpoints not met - May 2016
TRV027 - BLAST-AHF
Acute heart failure
Phase 1 trial complete.
TRV250
Acute migraine

Latest News

  1. Trevena (TRVN) Gains As Market Dips: What You Should Know
  2. Edited Transcript of TRVN earnings conference call or presentation 13-Mar-19 12:00pm GMT
  3. Will Trevena Continue to Surge Higher?
  4. Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
  5. Watch These Four Healthcare Stocks Set The Pace On Tuesday
  6. Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
  7. Trevena says it has 'clear path' to resubmit application for experimental pain medicine
  8. PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
  9. Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
  10. Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
  11. Trevena: 4Q Earnings Snapshot
  12. Trevena Reports Fourth Quarter and Full Year 2018 Results
  13. Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
  14. These Four Tech Stocks Could Test March Highs
  15. Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019
  16. How Much Of Trevena, Inc. (NASDAQ:TRVN) Do Institutions Own?
  17. Biotech Stocks Set to Pop
  18. Top Cannabis and Biotech Stocks To Watch
  19. Trevena to Present at the 21st Annual BIO CEO & Investor Conference